menu
    • menu
    [{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Atom Therapeutics","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Atom Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Atom Therapeutics \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"9","companyTruncated":"Atom Therapeutics \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Kaitai Capital","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Series D Financing","leadProduct":"Lingdolinurad","moa":"Urate transporter protein","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Atom Bioscience & Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Jiangsu Atom Bioscience & Pharmaceutical \/ Kaitai Capital","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Atom Bioscience & Pharmaceutical \/ Kaitai Capital"},{"orgOrder":0,"company":"Olatec Therapeutics","sponsor":"Sanders Morris Harris","pharmaFlowCategory":"D","therapeuticArea":"Rheumatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"Dapansutrile","moa":"NLRP3","graph1":"Rheumatology","graph2":"Phase II\/ Phase III","graph3":"Olatec Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rheumatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Olatec Therapeutics \/ Sanders Morris Harris","highestDevelopmentStatusID":"9","companyTruncated":"Olatec Therapeutics \/ Sanders Morris Harris"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Atom Therapeutics

                            China arrow
                            Iran Expo
                            Not Confirmed

                            Atom Therapeutics

                            China arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : China Medical System Holdings Limited

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Atom, CMS Partner on Lingdolinurad for Gout, Hyperuricemia Treatment

                            Details : The collaboration aims for the commercialization of ABP-671 (lingdolinurad), a novel oral small molecule URAT1 inhibitor for the treatment of chronic gout and hyperuricemia.

                            Product Name : ABP-671

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : China Medical System Holdings Limited

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            Iran Expo
                            Not Confirmed

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atom Bioscience Enrolling Patients In Global Phase 2b/3 Of Chronic Gout Treatment

                            Details : The company's primary product, ABP-671 a novel investigational orally administered URAT1 inhibitor, is currently undergoing Phase 2/3 clinical trials with patients for the treatment of chronic gout.

                            Product Name : ABP-671

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 24, 2024

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            Iran Expo
                            Not Confirmed

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Kaitai Capital

                            Deal Size : $83.0 million

                            Deal Type : Series D Financing

                            DEALS_DEV arrow-down

                            Atom Bioscience Raises $83M in a D-Round Financing to Support Global Pivotal Clinical Trials of ABP-671, a New...

                            Details : The financing will be used for completion of global pivotal clinical trials of ABP-671, its unique orally administered URAT1 inhibitor for chronic gout and to advance to clinical stage the company’s innovative pipeline of drugs for inflammatory and met...

                            Product Name : ABP-671

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            October 16, 2023

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Kaitai Capital

                            Deal Size : $83.0 million

                            Deal Type : Series D Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            Iran Expo
                            Not Confirmed

                            Jiangsu Atom Bioscience & Pharmaceutical

                            China arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Atom Bioscience Doses First Patient in Phase 2b/3 Clinical Trial of a New Treatment for Chronic Gout

                            Details : ABP-671 is a small molecule inhibitor of the urate transporter 1 (URAT1) protein, which is involved in the reabsorption of uric acid by the kidneys. In gout patients, ABP-671 reduces the reabsorption of uric acid, increasing its excretion in urine.

                            Product Name : ABP-671

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 10, 2023

                            Lead Product(s) : Lingdolinurad

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Olatec Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed

                            Olatec Therapeutics

                            U.S.A arrow
                            Iran Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dapansutrile

                            Therapeutic Area : Rheumatology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Sanders Morris Harris

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Olatec Therapeutics Announces the Final Closing, Led by Sanders Morris Harris, on Its $40 Million Series A Fin...

                            Details : The net proceeds will be used to advance OLT1177 (dapansutrile) into later stage clinical development. Dapansutrile is an investigational small molecule, that specifically binds to and blocks NLRP3, the sensor molecule integral in the formation of the NL...

                            Product Name : OLT1177

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 23, 2023

                            Lead Product(s) : Dapansutrile

                            Therapeutic Area : Rheumatology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Sanders Morris Harris

                            Deal Size : $40.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth